Objective:To analyze the value of D-dimer(D-D),interleukin-6(IL-6),and IL-18 in the differential diagnosis of children with refractory Mycoplasma pneumoniae pneumonia(RMPP).Methods:The medical records of 92 children w...Objective:To analyze the value of D-dimer(D-D),interleukin-6(IL-6),and IL-18 in the differential diagnosis of children with refractory Mycoplasma pneumoniae pneumonia(RMPP).Methods:The medical records of 92 children with Mycoplasma pneumoniae pneumonia(MPP)treated in the hospital were selected for retrospective analysis from January 2023 to January 2024.After comprehensive examinations such as computed tomography examination of the chest,48 children with general Mycoplasma pneumoniae pneumonia(GMPP)were put in the GMPP group and 44 children with RMPP were grouped in the RMPP group.The IL-6,IL-18,and D-D levels were compared between the two groups,and the receiver operating characteristic(ROC)curves were plotted to analyze their value for differential diagnosis of RMPP.Results:The levels of IL-6,IL-18,and D-D in the RMPP group were higher than those in the GMPP group(P<0.05);the ROC curves showed that the specificity of the differential diagnosis of IL-6,IL-18,and D-D was higher,and their diagnostic value was significant.Conclusion:Determination of IL-6,IL-18,and D-D levels in children with MPP can further diagnose the children’s condition,which can help physicians formulate targeted treatment plans,and is of great significance to the improvement of the children’s condition,which is worthy of attention.展开更多
目的:观察四妙丸对高尿酸性肾病患者血尿酸水平、肾功能及血清IL-1β、IL-18炎症因子分泌的影响。方法:选择90例高尿酸性肾病患者,随机分为非布司他组、四妙丸组和综合治疗组(非布司他+四妙丸),监测每组患者血尿酸、血肌酐水平,同时利用...目的:观察四妙丸对高尿酸性肾病患者血尿酸水平、肾功能及血清IL-1β、IL-18炎症因子分泌的影响。方法:选择90例高尿酸性肾病患者,随机分为非布司他组、四妙丸组和综合治疗组(非布司他+四妙丸),监测每组患者血尿酸、血肌酐水平,同时利用Elisa试剂盒测定血清IL-1β、IL-18炎症因子的分泌水平。结果:(1)血尿酸水平方面,非布司他组、综合治疗组2月时与0月相比即差异有统计学意义(414.03±41.21 vs 457.70±55.67,416.26±41.57 vs 486.56±63.32,P<0.05);四妙丸组3月时与0月比较差异有统计学意义(389.26±62.59 vs 456.23±66.77,P<0.05);3月时,综合治疗组与四妙丸组比较下降明显(353.0±70.12 vs 389.26.65±62.59,P<0.05)。(2)血肌酐水平方面,综合治疗组2月时与0月比较即明显降低(245.83±73.0 vs 311.76±88.48,P<0.05);四妙丸组3月时与0月比较显著下降(239.30±76.11 vs 291.50±94.72,P<0.05);3月时,与非布司他组相比,综合治疗组肌酐水平下降明显(209.9±56.62 vs 252.70±73.37,P<0.05);(3)血清炎症因子方面,非布司他组、四妙丸组、综合治疗组与0月时比较血清IL-1β水平(36.20±3.97 vs 40.0±5.89,29.66±7.62 vs 40.16±6.59,23.46±3.71 vs 41.63±4.88,P<0.05)、IL-18水平(67.13±3.27 vs 81.10±5.29,58.73±6.08 vs 78.76±4.90,49.93±5.13 vs 80.30±5.34,P<0.05)均显著下降;3月时,与非布司他组相比,四妙丸组、综合治疗组血清IL-1β水平(29.66±7.62 vs 36.20±3.97,23.46±3.71 vs 36.20±3.97,P<0.05)、IL-18水平(58.73±6.08 vs 67.13±3.27,49.93±5.13 vs 67.13±3.27,P<0.05)下降更为明显。结论:四妙丸能够通过降低血尿酸水平及抑制血清IL-1β、IL-18炎症因子的分泌对高尿酸性肾病患者产生肾脏保护作用。展开更多
文摘Objective:To analyze the value of D-dimer(D-D),interleukin-6(IL-6),and IL-18 in the differential diagnosis of children with refractory Mycoplasma pneumoniae pneumonia(RMPP).Methods:The medical records of 92 children with Mycoplasma pneumoniae pneumonia(MPP)treated in the hospital were selected for retrospective analysis from January 2023 to January 2024.After comprehensive examinations such as computed tomography examination of the chest,48 children with general Mycoplasma pneumoniae pneumonia(GMPP)were put in the GMPP group and 44 children with RMPP were grouped in the RMPP group.The IL-6,IL-18,and D-D levels were compared between the two groups,and the receiver operating characteristic(ROC)curves were plotted to analyze their value for differential diagnosis of RMPP.Results:The levels of IL-6,IL-18,and D-D in the RMPP group were higher than those in the GMPP group(P<0.05);the ROC curves showed that the specificity of the differential diagnosis of IL-6,IL-18,and D-D was higher,and their diagnostic value was significant.Conclusion:Determination of IL-6,IL-18,and D-D levels in children with MPP can further diagnose the children’s condition,which can help physicians formulate targeted treatment plans,and is of great significance to the improvement of the children’s condition,which is worthy of attention.
文摘目的:观察四妙丸对高尿酸性肾病患者血尿酸水平、肾功能及血清IL-1β、IL-18炎症因子分泌的影响。方法:选择90例高尿酸性肾病患者,随机分为非布司他组、四妙丸组和综合治疗组(非布司他+四妙丸),监测每组患者血尿酸、血肌酐水平,同时利用Elisa试剂盒测定血清IL-1β、IL-18炎症因子的分泌水平。结果:(1)血尿酸水平方面,非布司他组、综合治疗组2月时与0月相比即差异有统计学意义(414.03±41.21 vs 457.70±55.67,416.26±41.57 vs 486.56±63.32,P<0.05);四妙丸组3月时与0月比较差异有统计学意义(389.26±62.59 vs 456.23±66.77,P<0.05);3月时,综合治疗组与四妙丸组比较下降明显(353.0±70.12 vs 389.26.65±62.59,P<0.05)。(2)血肌酐水平方面,综合治疗组2月时与0月比较即明显降低(245.83±73.0 vs 311.76±88.48,P<0.05);四妙丸组3月时与0月比较显著下降(239.30±76.11 vs 291.50±94.72,P<0.05);3月时,与非布司他组相比,综合治疗组肌酐水平下降明显(209.9±56.62 vs 252.70±73.37,P<0.05);(3)血清炎症因子方面,非布司他组、四妙丸组、综合治疗组与0月时比较血清IL-1β水平(36.20±3.97 vs 40.0±5.89,29.66±7.62 vs 40.16±6.59,23.46±3.71 vs 41.63±4.88,P<0.05)、IL-18水平(67.13±3.27 vs 81.10±5.29,58.73±6.08 vs 78.76±4.90,49.93±5.13 vs 80.30±5.34,P<0.05)均显著下降;3月时,与非布司他组相比,四妙丸组、综合治疗组血清IL-1β水平(29.66±7.62 vs 36.20±3.97,23.46±3.71 vs 36.20±3.97,P<0.05)、IL-18水平(58.73±6.08 vs 67.13±3.27,49.93±5.13 vs 67.13±3.27,P<0.05)下降更为明显。结论:四妙丸能够通过降低血尿酸水平及抑制血清IL-1β、IL-18炎症因子的分泌对高尿酸性肾病患者产生肾脏保护作用。
